Olaparib 300mg tablets + Placebo to match olaparib 300mg
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Platinum Sensitive
Conditions
Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
Trial Timeline
Sep 3, 2013 → Dec 31, 2025
NCT ID
NCT01874353About Olaparib 300mg tablets + Placebo to match olaparib 300mg
Olaparib 300mg tablets + Placebo to match olaparib 300mg is a phase 3 stage product being developed by AstraZeneca for Platinum Sensitive. The current trial status is active. This product is registered under clinical trial identifier NCT01874353. Target conditions include Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01874353 | Phase 3 | Active |
Competing Products
20 competing products in Platinum Sensitive